Physician profile
Khalid M Bhatti
NPI 1497824114
$6,724.35
in general payments reported to CMS, 2019-2025
35 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $590 · 2021: $713 · 2022: $1,161 · 2023: $974 · 2024: $1,113 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260 · Education: $26.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.65 |
| Education | $26.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $931.96 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Vifor Pharma, INC. | $807.89 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $784.79 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Fresenius USA Marketing, INC. | $542.78 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $518.50 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $502.30 | 2021-2025 | |
| Akebia Therapeutics INC | $324.81 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $312.61 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $309.60 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $197.11 | 2023-2025 | |
| Glaxosmithkline, LLC. | $161.08 | 2020-2025 | Shingrix, Arexvy, Benlysta |
| Aurinia Pharma U.S., INC. | $146.01 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $144.78 | 2020-2025 | Terlivaz |
| Novo Nordisk INC | $128.74 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $112.16 | 2022-2023 | Krystexxa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $98.26 | 2025 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $85.22 | 2020-2023 | Gattex |
| Alexion Pharmaceuticals, INC. | $83.23 | 2019-2021 | |
| Lundbeck LLC | $69.87 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $61.15 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $56.48 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $50.62 | 2020-2024 | |
| Lilly USA, LLC | $42.07 | 2024-2025 | Jardiance |
| Nxstage Medical, INC. | $36.06 | 2024-2025 | Nxstage System One |
| Mallinckrodt Enterprises LLC | $34.93 | 2019 | |
| Pharmacosmos Therapeutics INC. | $24.96 | 2021 | |
| Cormedix INC. | $24.74 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $21.33 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $19.12 | 2021 | |
| Daiichi Sankyo INC. | $17.95 | 2020 | |
| Kyowa Kirin, INC. | $16.85 | 2023 | |
| Shire North American Group INC | $16.50 | 2019 | |
| Ani Pharmaceuticals, INC. | $14.25 | 2024 | Purified Cortrophin Gel |
| Strongbridge US INC. | $12.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.